This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

NATALEE is a global Phase III multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali® (ribociclib) with ET as an investigational adjuvant treatment versus ET ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

The CHMP recommended approval granting marketing authorization for Kisqali (ribociclib) for the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2 ...

has adopted a positive opinion and recommended granting marketing authorization for Kisqali ® (ribociclib) for the adjuvant treatment of adults with hormone receptor-positive/human epidermal ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...